The pediatric neurologist and sleep medicine specialist at Geisinger Medical Center discussed her talk given at SLEEP 2023 on the influence of obesity, asthma, metabolic syndrome, gut microbiome, and circadian rhythm on obstructive sleep apnea. [WATCH TIME: 4 minutes]
Nearly all patients showed improvement on the Patient Global Impression of Change scale, regardless of sleep inertia status, assessed through a visual analog scale.
The professor of neurology in the Division of Sleep Medicine at Harvard Medical School provided insight on current management of insomnia for children and adolescents, and where improvements could be made. [WATCH TIME: 3 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Following 13 weeks of treatment with once-nightly sodium oxybate, some patients in the 7.5 g and 9.0 g groups showed complete resolution of cataplexy attacks.
PUMAS significantly alleviated depression relative to controls whereas cognitive behavioral therapy-insomnia did not differ from either group.
The professor of neurology at Washington University School of Medicine discussed progressive multiple sclerosis and the need for targeted therapies to address the progression and associated challenges. [WATCH TIME: 5 minutes]
Among patients with post-acute sequelae from COVID-19 infection, self-reported cognitive symptoms were correlated with severity of fatigue, anxiety, and depression, but not subjective sleep disturbance.
In a study of 59 individuals with obstructive sleep apnea, solriamfetol yielded cognitive improvements at post-dose time points throughout the day, along with improvements in Patient Global Impression of Severity.
In the 2023 Donald Paty Lecture, speaker Darin Okuda presented novel MRI methods that might help determine whether MS lesions have potential for future remyelination.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Sleep Medicine.
Neurofilament light, a biomarker elevated in neurodegeneration and dementia, was higher among poor sleepers with Pittsburgh Sleep Quality Index scores of less than 5.
At CMSC 2023, the associate professor of neurological sciences at the University of Vermont in Burlington talked about data surrounding multiple sclerosis diagnosis and misdiagnosis, suggesting the need for the development of diagnostic biomarkers. [WATCH TIME: 5 minutes]
At CMSC 2023, the professor of neurology at Barts and The London School of Medicine and Dentistry discussed the emerging paradigm shift in understanding multiple sclerosis (MS) as a smoldering disease and the potential role of Epstein Barr Virus in causing MS. [WATCH TIME: 6 minutes]
Most patients completed at least 3 years of treatment, with no new safety signals observed and a treatment discontinuation rate of 5.3%.
The first results from a phase 2 study frexalimab (SAR441344; Sanofi), in relapsing multiple sclerosis have shown promise for the anti-CD40L antibody.
Although the CDC has declared the public health emergency for the COVID-19 pandemic over, patients with multiple sclerosis and other conditions are still in need of guidance.
Neurology News Network for the week ending June 2, 2023. [WATCH TIME: 3 minutes]
Using the Modified Fatigue Impact Scale, patients either forced to exercise or who volunteered saw significant improvements over a 12-week period.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 2, 2023.
At CMSC 2023, the neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed the importance of early intervention in speech and communication therapy, as well as the challenges faced in getting patients to seek therapy at the time of diagnosis. [WATCH TIME: 5 minutes]
The adjunct instructor at the UCSF Weill Institute for Neurosciences provided perspective on the next steps in research for potential wearable devices focused on treating issues of multiple sclerosis. [WATCH TIME: 2 minutes]
With few neuropalliative care services available in the US, the University of Rochester stands as a prime example of how a successful program can transform patient care.
Many programs and activities at the 2023 CMSC Annual Meeting focused on burnout prevention and supporting the current and future MS care workforce.
Factors such as older age, poor steroid responsiveness, and plasma exchange were associated with NMOSD phenotype, while normal or thinned retinal nerve fiber layer and short-segment hyperintensity were associated with idiopathic optic neuritis.
Jennifer Graves, MD, PhD, presented data at the CMSC annual meeting suggesting that secondary progressive disease might be more age-related than previously realized.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Brandon Giglio, MD. [LISTEN TIME: 17 minutes]
The combination of EDSS scores above 6 and age over 55 years resulted in higher serious infection rate that was nearly double that seen in the overall population.
In mixed-effect analyses adjusting for multiple cofounders, changes in inflammatory gene expression correlated inversely with changes in patient-reported stress, loneliness, hair cortisol, and aspects of interoceptive awareness.
In July, the FDA is expected to make a decision on lecanemab (Leqembi), an antiamyloid therapy previously approved under the accelerated approval pathway, for a potential traditional approval for early-stage Alzheimer disease.
